Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression
Imatinib mesylate is an anti-neoplastic targeted chemotherapeutic agent, which can inhibit tyrosine kinase receptors, including BCR-ABL, platelet-derived growth factor receptors (PDGFRs) and c-Kit. Cellular processes, including differentiation, proliferation and survival are regulated by these recep...
Main Authors: | Kadivar, Ali, Noordin, Mohamed Ibrahim, Aditya, Arya, Kamalidehghan, Behnam, Davoudi, Ehsan Taghizadeh, Sedghi, Reihaneh, Javar, Hamid Akbari |
---|---|
Format: | Article |
Published: |
Spandidos Publications
2018
|
Subjects: |
Similar Items
-
[Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression
by: Kadivar, Ali, et al.
Published: (2019) -
Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes
by: Kadivar, A., et al.
Published: (2017) -
Molecular Characterization of PDGFR-α/PDGF-A and c-KIT/SCF in Gliosarcomas
by: Rui M. Reis, et al.
Published: (2005-01-01) -
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
by: Michele Baccarani, et al.
Published: (2007-09-01) -
Endothelial Cells Promote Migration of Mesenchymal Stem Cells via PDGF-BB/PDGFRβ-Src-Akt in the Context of Inflammatory Microenvironment upon Bone Defect
by: Sihao He, et al.
Published: (2022-01-01)